All these findings reveal a new mechanism of regulation of HER2 activity, and support the existence HER2-CB2R heteromers as novel therapeutic targets for HER2+ breast cancer (Pérez-Gómez et al., 2015; Blasco-Benito et al., 2019). This evidence concerns the gene ERBB2 and breast cancer.